CompletedNot Applicable

Effects of OAGB and DJB-SG on 10-year and Lifetime Risks of MACE

830 participantsStarted 2011-01-01

Plain-language summary

Metabolic bariatric surgery (MBS) has demonstrated its efficacy in achieving sustainable weight loss and alleviating associated comorbidities. The primary objective of our investigation is to assess the long-term impact and sustainability of weight loss, the remission of T2D as well as risk prediction of cardiovascular events following MBS concerning one-anastomosis gastric bypass (OAGB) and duodenojejunal bypass with sleeve gastrectomy (DJB-SG).

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients whose BMI≧37.5 kg/m2 or patients whose BMI≧32.5 kg/m2 and have concurrent high-risk comorbidities, such as hypertension, obstructive sleep apnea, HbA1c≧7.5% after anti-diabetic medication treatment, etc; * The patients have been treated with lifestyle intervention, including increase in physical activity and change in diet, for more than 6 months; * Age between 20 and 65 years old; * Patients without other endocrinological causes that result in morbid obesity; * Patients without substance use, alcohol use and other psychiatric disorders; * The integrity of the patient's mental status is approved by the psychiatrist. Exclusion Criteria: * Patients who did not complete 3-year follow-up * Patients who are not eligible for surgery

What they're measuring

Body Mass Index (BMI)

Timeframe: 3 years

Diabetes

Timeframe: 3 years

Hypertension

Timeframe: 3 years

Dyslipidemia

Timeframe: 3 years

Trial details

NCT IDNCT06254339

SponsorNational Defense Medical Center, Taiwan

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-12-31

View on ClinicalTrials.gov More Obesity trials